Goldman Sachs Maintains Buy on Compass, Lowers Price Target to $12

Goldman Sachs maintains Compass (NYSE:COMP) with a Buy and lowers the price target from $21 to $12.

byBenzinga Newsdesk

March 31, 2022

1 minute read

Goldman Sachs maintains Compass (NYSE:COMP) with a Buy and lowers the price target from $21 to $12.

Datadog Sees Q3 Adj. EPS $0.05-$0.06 vs $0.03 Est., Sales $246M-$248M vs $226.01M Est.; Sees FY21 Adj. EPS $0.26-$0.28 vs $0.16 Est., Sales $938M-$944M vs $886.16M Est.

By Bill Haddad

Today, 11:55 PM

d on information as of today, August 5, 2021, Datadog is providing the following guidance: Third Quarter 2021 Outlook: Revenue between $246 million and $248 million. Non-GAAP

DDOG

FDA
News

Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults

By Michael Horton

Today, 11:55 PM

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) today announced that the U.S. Food and Drug Administration (FDA) approved Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of

JAZZ